These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 33149591)

  • 1. Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia.
    Tsegay EW; Demise DG; Hailu NA; Gufue ZH
    Neuropsychiatr Dis Treat; 2020; 16():2499-2509. PubMed ID: 33149591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin model of schizophrenia: emerging role of glutamate mechanisms.
    Aghajanian GK; Marek GJ
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):302-12. PubMed ID: 10719157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine H
    Mahmood D
    Int J Health Sci (Qassim); 2016 Oct; 10(4):564-575. PubMed ID: 27833522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
    López-Gil X; Artigas F; Adell A
    Curr Pharm Des; 2010; 16(5):502-15. PubMed ID: 19909228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia].
    Maćkowiak M; Czyrak A; Wedzony K
    Psychiatr Pol; 2000; 34(4):607-21. PubMed ID: 11059260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine release in the nucleus accumbens and latent inhibition in the rat following microinjections of a 5-HT1B agonist into the dorsal subiculum: implications for schizophrenia.
    Boulenguez P; Peters SL; Mitchell SN; Chauveau J; Gray JA; Joseph MH
    J Psychopharmacol; 1998; 12(3):258-67. PubMed ID: 10958252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
    Arnt J; Bang-Andersen B; Grayson B; Bymaster FP; Cohen MP; DeLapp NW; Giethlen B; Kreilgaard M; McKinzie DL; Neill JC; Nelson DL; Nielsen SM; Poulsen MN; Schaus JM; Witten LM
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1021-33. PubMed ID: 20569520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT6 receptors: a novel target for cognitive enhancement.
    Mitchell ES; Neumaier JF
    Pharmacol Ther; 2005 Dec; 108(3):320-33. PubMed ID: 16005519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could the 5-HT1B receptor inverse agonism affect learning consolidation?
    Meneses A
    Neurosci Biobehav Rev; 2001 Mar; 25(2):193-201. PubMed ID: 11323083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.
    De Deurwaerdère P; Navailles S; Berg KA; Clarke WP; Spampinato U
    J Neurosci; 2004 Mar; 24(13):3235-41. PubMed ID: 15056702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
    Yoshikawa S; Hareyama N; Ikeda K; Kurokawa T; Nakajima M; Nakao K; Mochizuki H; Ichinose H
    Eur J Pharmacol; 2009 Mar; 606(1-3):102-8. PubMed ID: 19374836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.
    Gobert A; Rivet JM; Audinot V; Newman-Tancredi A; Cistarelli L; Millan MJ
    Neuroscience; 1998 May; 84(2):413-29. PubMed ID: 9539213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the central cholinergic system in the therapeutics of schizophrenia.
    Terry AV
    Curr Neuropharmacol; 2008 Sep; 6(3):286-92. PubMed ID: 19506725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.